Regeneron Pharmaceuticals Stock News

Regeneron Pharmaceuticals: Undervalued Cash Generating Machine

Regeneron (REGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) fell by over 5% in the previous trading session. This is why it happened.

Is (REGN) Outperforming Other Medical Stocks This Year?

Core PCE Inflation Stays at Record-High in August.

Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitali

TARRYTOWN, N.Y., Sept. 30, 2021 /PRNewswire/ --  Trial met primary endpoint, showing REGEN-COV significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized wi

TARRYTOWN, N.Y., Sept. 29, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results

These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cantor Fitzgerald Virtual Global Healthcare 2021 Conference (Transcript)

Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.

The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited production of Regeneron Pharmace

We have narrowed down our search to five large-cap stocks that have given double-digit returns in the past three months. These are: CLR, DAR, REGN, ORLY and MOS.

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.08% were down 0.1% in premarket trading on Friday after the World Health Organization recommended its monoclonal antibody as a treatment for COVID-19.